GSK files Eperzan (albiglutide) at EMA for treatment of Type 2 Diabetes
GSK has announced the submission of a Marketing Authorisation Application for albiglutide, with the proprietary name Eperzan to the European Medicines Agency. Albiglutide is an investigational once-weekly treatment for adult patients with Type 2 Diabetes which is not yet approved anywhere in the world.
On 14th January 2013, GSK announced the submission of a regulatory application in the United States for albiglutide under the name Syncria. Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of Type 2 Diabetes designed for once-weekly subcutaneous dosing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.